Teva's new drug nears EU approval

Zev Stub, "Teva's new drug nears EU approval" (18 November 2004, Jerusalem Post)
Leading text: "Teva Pharmaceutical Industries' Parkinson's disease (PD) treatment Azilect (rasagiline) has been recommended for market approval in the European Union. The announcement should help boost Teva's stock, as it indicates that market approvals for the highly-touted drug may be closer than expected, said David Moskowitz, an analyst for Friedman, Billings, Ramsey in Arlington, Virginia..."[FullText]